Increased loss‐of‐function filaggrin gene mutation prevalence in atopic dermatitis patients across northern latitudes indicates genetic fitness: A systematic review and meta‐analysis

• Published in: Experimental dermatology 2024-07, Vol.33 (7), p.e15130-n/a
• Main Authors: Khatib, Casper Milde, Klein‐Petersen, Amalie Wandel, Rønnstad, Amalie Thorsti Møller, Egeberg, Alexander, Christensen, Maria Oberländer, Silverberg, Jonathan Ian, Thomsen, Simon Francis, Irvine, Alan David, Thyssen, Jacob Pontoppidan
• Format: Article
• Language: English
• Subjects: Atopic dermatitis; Dermatitis; Dermatitis, Atopic - epidemiology; Dermatitis, Atopic - genetics; Filaggrin; Filaggrin Proteins; Genetic analysis; Genetic Fitness; Genetic Predisposition to Disease; Humans; Intermediate Filament Proteins - genetics; Latitude; Loss of Function Mutation; Meta-analysis; Mutation; Point mutation; Population genetics; Population studies; Prevalence; Systematic review
• ISSN: 0906-6705; 1600-0625; 1600-0625
• DOI: 10.1111/exd.15130

Loss‐of‐function (LoF) mutations in the filaggrin gene (FLG) constitute the strongest genetic risk for atopic dermatitis (AD). A latitude‐dependent difference in the prevalence of LoF FLG mutations was systematically evaluated. A systematic review and meta‐analysis were performed to estimate the prevalence of LoF FLG mutations in AD patients and the general population by geography and ethnicity. Risk of bias was assessed by Newcastle‐Ottawa Scale and Jadad score. StatsDirect, version 3 software was used to calculate all outcomes. PubMed and EMBASE were searched until 9th December 2021. Studies were included if they contained data on the prevalence of LoF FLG mutations in AD patients or from the general population or associations between AD and LoF FLG mutations and were authored in English. Overall, 248 studies and 229 310 AD patients and individuals of the general population were included in the quantitative analysis. The prevalence of LoF FLG mutations was 19.1% (95% CI, 17.3–21.0) in AD patients and 5.8% (95% CI, 5.3–6.2) in the general population. There was a significant positive association between AD and LoF FLG mutations in all latitudes in the Northern hemisphere, but not in all ethnicities. The prevalence of LoF FLG mutations became gradually more prevalent in populations residing farther north of the Equator but was negligible in Middle Easterners and absent in most African populations. FLG LoF mutations are common and tend to increase with northern latitude, suggesting potential clinical implications for future AD management. The existence of possible genetic fitness from FLG LoF mutations remains unknown.